Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Newcastle
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Newcastle, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 13 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche5 Eli Lilly and Company4 Janssen Research & Development, LLC2 AstraZeneca2 Microbiotica Ltd1
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Newcastle

53 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease
DrugAOC 1044
Avidity Biosciences, Inc.
Phase 3
70
Newcastle, Oxford
2026-09-01
Recruiting
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Recruiting
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Recruiting
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
AstraZeneca
Phase 2
230
Birmingham, Cambridge, Cardiff, Newcastle
2025-12-10
Recruiting
Eli Lilly and Company
Phase 3
7,140
Birmingham, Blackpool, Bromborough, Newcastle, Newquay, Poole, Rotherham, Torpoint
2025-12-01
Recruiting
Hoffmann-La Roche
Phase 3
900
Dundee, Exeter, London, Newcastle, Oxford, Plymouth,Devon
2025-11-24
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Gloucester, London, Newcastle, Southampton, Sunderland, York, Belfast
2025-10-28
Recruiting
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield
2025-09-29
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
Pharmazz, Inc.
Phase 3
514
Bury, London, Southampton, Wolverhampton, Harrow, Newcastle, Stoke-on-Trent
2025-07-24
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Cambridge, Newcastle, Oxford
2025-07
Recruiting
Eli Lilly and Company
Phase 2
200
Birmingham, Blackpool, Bristol, Bromborough, Newcastle, Newquay, Nuneaton, Poole
2025-03-28
Recruiting
Inari VISION Registry
NCT06600542Pulmonary Embolism
Inari Medical
Observational
1,000
Bristol, Glasgow, London, Newcastle, Swindon
2025-03-07
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Bristol, Cambridge, London, Newcastle
2025-02-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Bristol, Exeter, Newcastle, Norwich, Northamptonshire, Bicester, Oxford, Somerset
2024-12-02
Active, closed
Santhera Pharmaceuticals
Phase 4
80
Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle
2024-11-10
Active, closed
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Cambridge, Clydebank, London, Newcastle, Sheffield
2024-09-03
Active, closed
Microbiotica Ltd
Phase 1
41
Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton
2024-08-28
Active, closed
Kite, A Gilead Company
Phase 3
452
Bristol, Cardiff, Leeds, London, Newcastle
2024-08-23
Active, closed
Ferrer Internacional S.A.
Phase 2
241
Cambridge, London, Newcastle, Southampton
2024-07-23
Recruiting
Translumina Therapeutics Pvt Ltd.
Observational
2,000
Bedford, Newcastle, Plymouth, Salisbury, Wigan
2024-01-10
Active, closed
BioNTech SE
Phase 1
41
London, Manchester, Newcastle
2023-11-30
By invitation
Edgewise Therapeutics, Inc.
Phase 2
260
Salford, London, Newcastle
2023-11-02
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Brighton, Lincoln, London, Londonderry, Newcastle, Newcastle upon Tyne, Plymouth, Worcester
2023-04-25
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Active, closed
COMPASS Pathways
Phase 3
572
Bodmin, Chertsey, Chester, Doncaster, Exeter, Fulbourn, London, Newcastle
2023-02-14
Active, closed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
Complement Therapeutics
Observational
250
Belfast, Bradford, Frimley, Gloucester, Liverpool, London, Manchester, Newcastle
2023-02-07
Recruiting
Pharming Technologies B.V.
Phase 2
180
Cambridge, London, Newcastle
2022-12-13
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Nottingham, Exeter, Liverpool, London, Newcastle, Swansea
2022-05-03
Active, closed
Precise Procedural and PCI Plan (P4)
NCT05253677Coronary Artery Disease
CoreAalst BV
Not applicable
1,090
Poole, Clydebank, Liverpool, London, Newcastle
2022-04-01
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle
2022-01-13
Active, closed
JOTEC GmbH
Observational
108
Cottingham, London, Newcastle
2021-10-20
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
Active, closed
HistoSonics, Inc.
Not applicable
24
Leeds, Newcastle
2021-06-04
Active, closed
Hoffmann-La Roche
Phase 2
586
Dundee, London, Newcastle, Oxford, Peterborough, Plymouth
2021-05-05
Active, closed
Helmholtz Zentrum München
Not applicable
1,149
Cambridge, Newcastle
2021-04-22
Active, closed
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Active, closed
XVIVO Perfusion
Not applicable
230
Newcastle, Birmingham, Cambridge
2020-11-25
Active, closed
Prospective and Non-randomized Registry of CardioCel 3D
NCT04175327Intracardiac and Septal Defects, Valve and Anulus Repair, Great Vessel Reconstruction, Peripheral Vessel Reconstruction
LeMaitre Vascular
Observational
200
Bristol, Newcastle
2020-08-28
Active, closed
LAM561 With RT and TMZ for Adults With Glioblastoma
NCT04250922Primary Glioblastoma, Glioblastoma Multiforme
DrugLAM561
Laminar Pharmaceuticals
Phase 2/3
144
Newcastle, Birmingham, Cambridge, London
2019-12-01
Active, closed
NeuroDerm Ltd.
Phase 3
381
London, Newcastle, Plymouth
2019-09-30
Recruiting
Boston Scientific Corporation
Observational
1,500
Bristol, Glasgow, Liverpool, London, Newcastle, Oxford
2014-03-04
Active, closed
Zimmer POLAR Persona - TKA (EMEA Study)
NCT02337244Severe Knee Pain, Severe Knee Disability, Osteoarthritis, Rheumatoid Arthritis
Zimmer, GmbH
Observational
777
Leeds, Clydebank, Harrogate, Newcastle
2013-11-18
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Cardiff, Exeter, London, Manchester, Newcastle, Southampton, Wales
2013-03-18
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-uk/city/newcastle

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 13 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies with a site in Newcastle.

How many clinical trials are recruiting in Newcastle?

24 of the 53 studies on this page are recruiting new participants as of the 13 Oct 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 27 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Newcastle), 53 studies
PhaseStudiesRecruitingShare
Phase 317932.1%
Observational11520.8%
Phase 28515.1%
Not applicable509.4%
Phase 1427.5%
Phase 1/2427.5%
Phase 4315.7%
Phase 2/3101.9%

Most active sponsors

Lead sponsors with the most studies (Newcastle)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche51
Eli Lilly and Company44
AstraZeneca22
Janssen Research & Development, LLC20
Alexion Pharmaceuticals, Inc.11
Alfasigma S.p.A.11
Amgen10
Avidity Biosciences, Inc.11
BioNTech SE10
Boston Scientific Corporation11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.